Naltrexone and Nalmefene as Modern Psychopharmacotherapy for Alcohol Use Disorder: Modulation of Opioid Receptors and Neurobiological Pathways of Alcohol Action

Maciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek · 2026

Read Naltrexone and Nalmefene as Modern Psychopharmacotherapy for Alcohol Use Disorder: Modulation of Opioid Receptors and Neurobiological Pathways of Alcohol Action by Maciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297373.txt.

Description

Two established medicines for alcohol dependence get a side-by-side appraisal in a 2026 review led by Maciej Rząca and colleagues. The authors weigh naltrexone and nalmefene, drugs that act on opioid receptors, and ask how each one performs against drinking outcomes that matter in practice.

Outcomes centered on total alcohol consumption and monthly heavy drinking days, alongside safety, side effects, dropout, and dosing convenience. Nalmefene, taken only when needed, cut both measures, with gains appearing within the first month and holding through follow-up. Naltrexone performed comparably in pooled analyses, and its long-acting injection eased dosing for some patients. Common side effects were mild, mainly nausea and dizziness.

Catalog record

CREATORMaciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74557
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13297373

Browse the full library · About the Tower of Babel